Predicting the development of cardiac allograft vasculopathy

Cardiovascular Pathology

Volumn 23, Issue 5, 2014, Pages 253-260

  Seki, Atsuko ^a   Fishbein, Michael C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac allograft vasculopathy; Chronic rejection; Heart transplantation

Indexed keywords

ANTIBODY; AZATHIOPRINE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC MYOSIN; CATECHOLAMINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; DONOR SPECIFIC ANTIBODY; EVEROLIMUS; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA ANTIBODY; HLA ANTIGEN CLASS 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 17; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THROMBOCYTE FACTOR 4; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; VASCULOTROPIN C; VIMENTIN; VON WILLEBRAND FACTOR;

AGE; ANGIOCARDIOGRAPHY; ANTIBODY MEDIATED REJECTION; ATHEROSCLEROSIS; AUTOIMMUNITY; B LYMPHOCYTE; BRAIN DEATH; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CHRONIC GRAFT REJECTION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBROMUSCULAR DYSPLASIA; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; INSULIN RESISTANCE; INTRAVASCULAR ULTRASOUND; MACROPHAGE; MEDICAL HISTORY; MYOCARDIAL PERFUSION IMAGING; NONHUMAN; OBESITY; PATHOGENESIS; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREDICTION; PREVALENCE; PRIMARY GRAFT DYSFUNCTION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SMOKING; SMOOTH MUSCLE FIBER; STEM CELL; STRESS ECHOCARDIOGRAPHY; SUDDEN CARDIAC DEATH; SURVIVAL RATE; THORAX PAIN; THROMBOCYTE ACTIVATION; VASCULITIS; ADVERSE EFFECTS; ALLOGRAFT; GRAFT REJECTION; HEART DISEASES; IMMUNOLOGY;

ALLOGRAFTS; GRAFT REJECTION; GRAFT SURVIVAL; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; RISK FACTORS;

EID: 84908481557     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2014.05.001     Document Type: Review

References (56)

1. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report-2013; focus theme: age. J Heart Lung Transplant 2013;32(10):951-64.
2. Rodriguez Cetina Biefer H, Sundermann SH, Emmert MY, Enseleit F, Seifert B, Ruschitzka F, et al. Surviving 20 years after heart transplantation: a success story. Ann Thorac Surg 2014;97(2):499-504.
3. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, et al. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant 2013;32(1):120-8.
4. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010;29(7):717-27.
5. Lu WH, Palatnik K, Fishbein GA, Lai C, Levi DS, Perens G, et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant 2011;30(9):1044-50.
6. Segura AM, Buja LM. Cardiac allograft vasculopathy: a complex multifactorial sequela of heart transplantation. Texas Heart Institute journal/from the Texas Heart Institute of St Luke's Episcopal Hospital, Texas Children's Hospital, 40(4); 2013. p. 400-2.
7. Miller CA, Sarma J, Naish JH, Yonan N, Williams SG, Shaw SM, et al. Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy. J Am Coll Cardiol 2014;63(8):799-808.
8. Benatti RD, Taylor DO. Evolving concepts and treatment strategies for cardiac allograft vasculopathy. Curr Treat Options Cardiovasc Med 2014;16(1):278.
9. Mittal TK, Panicker MG, Mitchell AG, Banner NR. Cardiac allograft vasculopathy after heart transplantation: electrocardiographically gated cardiac CT angiography for assessment. Radiology 2013;268(2):374-81.
10. Chantranuwat C, Blakey JD, Kobashigawa JA, Moriguchi JD, Laks H, Vassilakis ME, et al. Sudden, unexpected death in cardiac transplant recipients: an autopsy study. J Heart Lung Transplant 2004;23(6):683-9.
11. Chen YJ, Lam J, Gregory CR, Schrepfer S, Wulff H. The Ca(2+)-Activated K(+) Channel KCa3.1 as a potential newtarget for the prevention of allograft vasculopathy. PLoS ONE 2013;8(11):e81006.
12. Zakliczynski M, Babinska A, Flak B, Nozynski J, Kamienska N, Szygula-Jurkiewicz B, et al. Persistent mild lesions in coronary angiography predict poor long-term survival of heart transplant recipients. J Heart Lung Transplant 2013;33(6):618-23.
13. Modjeski KL, Morrell CN. Small cells, big effects: the role of platelets in transplant vasculopathy. J Thromb Thrombolysis 2014;37(1):17-23.
14. Castellani C, Angelini A, de Boer OJ, van der Loos CM, Fedrigo M, Frigo AC, et al. Intraplaque hemorrhage in cardiac allograft vasculopathy. Am J Transplant 2014;14(1):184-92.
15. Jane-Wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC, et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kappaB signaling in endothelial cells. Circulation 2013;128(23):2504-16.
16. Kalache S, Dinavahi R, Pinney S, Mehrotra A, Cunningham MW, Heeger PS. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immunol 2011;187(2):1023-30.
17. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006;6(6):1248-56.
18. Costello JP, Mohanakumar T, Nath DS. Mechanisms of chronic cardiac allograft rejection. Texas Heart Institute journal/from the Texas Heart Institute of St Luke's Episcopal Hospital, Texas Children's Hospital, 40(4); 2013. p. 395-9.
19. Wang H, Zhang Z, Tian W, Liu T, Han H, Garcia B, et al. Memory T cells mediate cardiac allograft vasculopathy and are inactivated by anti-OX40L monoclonal antibody. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy; 2013.
20. Salama M, Andrukhova O, Roedler S, Zuckermann A, Laufer G, Aharinejad S. Association of CD14+ monocyte-derived progenitor cells with cardiac allograft vasculopathy. J Thorac Cardiovasc Surg 2011;142(5):1246-53.
21. Mehra MR, Uber PA, Ventura HO, Scott RL, Park MH. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 2004;43(5):806-10.
22. Nytroen K, Rustad LA, Erikstad I, Aukrust P, Ueland T, Lekva T, et al. Effect of high-intensity interval training on progression of cardiac allograft vasculopathy. J Heart Lung Transplant 2013;32(11):1073-80.
23. Petrossian GA, Nichols AB, Marboe CC, Sciacca R, Rose EA, Smith CR, et al. Relation between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation 1989;80(5 Pt. 2):Iii122-5.
24. Suciu-Foca N, Reed E, Marboe C, Harris P, Yu PX, Sun YK, et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991;51(3):716-24.
25. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008;117(16):2131-41.
26. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organs Transplant 2010;15(1):16-20.
27. Nath DS, Ilias Basha H, Tiriveedhi V, Alur C, Phelan D, Ewald GA, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010;29(11):1277-85.
28. Kwon MH, Wong SY, Ardehali A, Laks H, Zhang ZK, Deng MC, et al. Primary graft dysfunction does not lead to increased cardiac allograft vasculopathy in surviving patients. J Thorac Cardiovasc Surg 2013;145(3):869-73.
29. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007;20(4):425-31.
30. Costanzo MR, Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29(8):914-56.
31. Sanchez Lazaro IJ, Almenar Bonet L, Moro Lopez J, Sanchez Lacuesta E, Martinez-Dolz L, Aguero Ramon-Llin J, et al. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation. Transplant Proc 2008;40(9):3056-7.
32. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333(10):621-7.
33. Raichlin ER, McConnell JP, Lerman A, Kremers WK, Edwards BS, Kushwaha SS, et al. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. J Heart Lung Transplant 2007;26(8):826-33.
34. Caretta N, Feltrin G, Tarantini G, D'Agostino C, Tona F, Selice R, et al. Low serum testosterone as a new risk factor for chronic rejection in heart transplanted men. Transplantation 2013;96(5):501-5.
35. Karamichalis JM, Miyamoto SD, Campbell DN, Smith J, McFann KK, Clark S, et al. Pediatric cardiac retransplant: differing patterns of primary graft failure by age at first transplant. J Thorac Cardiovasc Surg 2011;141(1):223-30.
36. Topilsky Y, Hasin T, Raichlin E, Boilson BA, Schirger JA, Pereira NL, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2012;125(5):708-20.
37. Hirt SW, Bara C, Barten MJ, Deuse T, Doesch AO, Kaczmarek I, et al. Everolimus in heart transplantation: an update. J Transplant 2013;2013:683964.
38. Vrtovec B, Haddad F, Pham M, Deuse T, Fearon WF, Schrepfer S, et al. Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients. Transplant Proc 2013;45(6):2406-9.
39. Garrido IP, Garcia-Lara J, Pinar E, Pastor-Perez F, Sanchez-Mas J, Valdes-Chavarri M, et al. Optical coherence tomography and highly sensitivity troponin T for evaluating cardiac allograft vasculopathy. Am J Cardiol 2012;110(5):655-61.
40. Pethig K, Heublein B, Kutschka I, Haverich A. Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 2000;102(19 Suppl 3):Iii233-6.
41. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008;117:2131-41.
42. Mehra MR, Uber PA, Potluri S, Ventura HO, Scott RL, Park MH. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 2004;94(4):454-8.
43. Mehra MR, Uber PA, Walther D, Vesely M, Wohlgemuth JG, Prentice J, et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker. Circulation 2006;114(1 Suppl):I21-6.
44. Chamorro CI, Almenar L, Martinez-Dolz L, Reganon E, Sanchez-Lacuesta E, Villa P, et al. Usefulness of von Willebrand factor in cardiac allograft vasculopathy: preliminary experience. Transplant Proc 2006;38(8):2566-8.
45. Martinez-Dolz L, Almenar L, Reganon E, Vila V, Chamorro C, Andres L, et al. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy. J Heart Lung Transplant 2008;27(7):760-6.
46. Singh N, Van Craeyveld E, Tjwa M, Ciarka A, Emmerechts J, Droogne W, et al. Circulating apoptotic endothelial cells and apoptotic endothelial microparticles independently predict the presence of cardiac allograft vasculopathy. J Am Coll Cardiol 2012;60(4):324-31.
47. Lin D, Cohen Freue G, Hollander Z, John Mancini GB, Sasaki M, Mui A, et al. Plasma protein biosignatures for detection of cardiac allograft vasculopathy. J Heart Lung Transplant 2013;32(7):723-33.
48. Yamani MH, Taylor DO, Rodriguez ER, Cook DJ, Zhou L, Smedira N, et al. Transplant vasculopathy is associated with increased AlloMap gene expression score. J Heart Lung Transplant 2007;26(4):403-6.
49. Li L, Khush K, Hsieh SC, Ying L, Luikart H, Sigdel T, et al. Identification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejection. PLoS ONE 2013;8(12):e82153.
50. Brittain EL, Hemnes AR. One generation's "junk" is another's treasure: the emerging role of microRNAs as therapeutic targets. J Heart Lung Transplant 2014;33(3):233-4.
51. Mas VR, Dumur CI, Scian MJ, Gehrau RC, Maluf DG. MicroRNAs as biomarkers in solid organ transplantation. Am J Transplant 2013;13(1):11-9.
52. Wang E, Nie Y, Zhao Q, Wang W, Huang J, Liao Z, et al. Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. J Cardiothorac Surg 2013;8:165.
53. Sukma Dewi I, Torngren K, Gidlof O, Kornhall B, Ohman J. Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. J Heart Lung Transplant 2013;32(4):463-6.
54. Zhou L, Zang G, Zhang G, Wang H, Zhang X, Johnston N, et al. MicroRNA and mRNA signatures in ischemia reperfusion injury in heart transplantation. PLoS ONE 2013;8(11):e79805.
55. Qin L, Huang Q, Zhang H, Liu R, Tellides G, Min W, et al. SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function. J Am Coll Cardiol 2014;63(1):21-9.
56. De Souza AI, Wait R, Mitchell AG, Banner NR, Dunn MJ, Rose ML. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ Res 2005;97(2):192-8.